PTC Therapeutics Inc. Common Stock (PTCT)
Stock · NASDAQ · Health Care
$59.27as of 10/16/2026
Price chart
Active signals
PTCT Signal Track Record
How signals performed across all stocks →What PTCT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +0.3% | 51% | September 18, 2026 |
| Bollinger Band Breakout | 27 | -1.2% | 48% | June 15, 2026 |
| Bollinger Band BreakdownActive now | 23 | +6.9% | 65% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +4.1% | 57% | August 25, 2026 |
| Any 20-session window (baseline) | +1.6% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; T…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 991
- Website
- www.ptcbio.com/
Fundamentals
- 1-day range
- $58.98$61.73
- Market cap
- $5.91B
- P/E (trailing)
- —
- P/E (forward)
- 25.00
- EPS (trailing)
- $-0.59
- Dividend yield
- —
- Beta
- 0.50
- Avg. volume
- 1.12M
How PTC Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
PTC Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
- TVTXTravere Therapeutics Inc. Common Stock$49.6▼ 6.04%Market cap $5.89BP/E —$22.59$68.73
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- AMRXAmneal Pharmaceuticals Inc. Class A Common Stock$19.18▼ 0.36%Market cap $5.76BP/E 39.88$9.56$21.18
- MIRMMirum Pharmaceuticals Inc. Common Stock$80.14▼ 2.73%Market cap $5.74BP/E —$63.23$130
- DNTHDianthus Therapeutics Inc. Common Stock$72.09▼ 3.27%Market cap $6.15BP/E —$32.22$117.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
| TVTX Travere Therapeutics Inc. Common Stock | $5.89B | — | $49.6 | ▼ 6.04% | $22.59$68.73 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| AMRX Amneal Pharmaceuticals Inc. Class A Common Stock | $5.76B | 39.88 | $19.18 | ▼ 0.36% | $9.56$21.18 |
| MIRM Mirum Pharmaceuticals Inc. Common Stock | $5.74B | — | $80.14 | ▼ 2.73% | $63.23$130 |
| DNTH Dianthus Therapeutics Inc. Common Stock | $6.15B | — | $72.09 | ▼ 3.27% | $32.22$117.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75benzinga · 10/8/2026
- RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75Benzinga · 10/8/2026
- Is PTC Stock Increasing Your Market Risk?Yahoo · 10/6/2026
- Which Gives You More Of Hard-To-Replace Software, PTC Or Fair Isaac?Yahoo · 9/30/2026
- 2026 Philadelphia ORBIE Awards Honor Top Technology and Security Executives in PhiladelphiaYahoo · 9/28/2026
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/25/2026
- Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137Benzinga · 9/22/2026
- PTC Completes Acquisition of ST-920 Fabry Disease Gene TherapyYahoo · 9/21/2026
- PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline ProgressYahoo · 9/20/2026
Insider Activity
Insider Actions →- Michael Schmertzler · October 7, 2026 · Sale53 @ $63.95
- Michael Schmertzler · October 7, 2026 · Sale2.4K @ $63.38
- Mark Elliott Boulding · October 6, 2026 · Option Exercise435 @ $39.42
- Mark Elliott Boulding · October 6, 2026 · Sale435 @ $64.16
- Mark Elliott Boulding · October 5, 2026 · Option Exercise1.6K @ $39.42
- Mark Elliott Boulding · October 5, 2026 · Sale1.6K @ $64.03
- STEELE GLENN JR MD PHD · September 30, 2026 · Option Exercise12.0K @ $11.23
- STEELE GLENN JR MD PHD · September 30, 2026 · Sale12.0K @ $65.16
- Michael Schmertzler · September 17, 2026 · Sale376 @ $68.45
- Michael Schmertzler · September 17, 2026 · Sale9.6K @ $67.83
- Michael Schmertzler · September 16, 2026 · Sale7.0K @ $67.35
- Michael Schmertzler · September 16, 2026 · Sale3.0K @ $66.58
- Michael Schmertzler · September 10, 2026 · Sale10.0K @ $67.34
- Michael Schmertzler · September 9, 2026 · Sale9.4K @ $67.79
- Michael Schmertzler · September 9, 2026 · Sale572 @ $68.67
Institutional Ownership
March 31, 2026
- Total shares held
- 90.57M
- Total value held
- $6.02B
- Institutional holders
- 343
- Unknown12.95M
- Unknown7.75M
- Unknown7.19M
- Unknown4.35M
- Unknown3.94M
- Unknown3.68M
- Unknown3.03M
- Unknown2.46M
- Unknown2.21M
- Unknown1.89M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29
PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29. PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.